Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.45 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.37 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.35 |
| ▸ | TK1 | P04183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035974 | 0.87 | DUT (0.47) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL629553 | 0.87 | DUT (0.45) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15414026 | 0.85 | DUT (0.46) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15771583 | 0.84 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL414704 | 0.84 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL25752564 | 0.81 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL6034458 | 0.81 | DUT (0.53) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL249821 | 0.79 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL28745696 | 0.79 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL2056622 | 0.79 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119033822-A | Compositions and methods for inhibiting seizures | 加利福尼亚大学董事会 | 2024-11-29 | — | — | CN | disclosed |
| CN-110325196-B | Compositions and methods for inhibiting seizures | 加利福尼亚大学董事会 | 2024-08-27 | — | — | CN | disclosed |
| CN-101198320-B | Herpesvirus-derived therapeutic agent for pain | JUNTENDO EDUCATIONAL FOUNDATION | 2012-03-07 | — | — | CN | disclosed |
| US-7897645-B2 | Herpesvirus-derived therapeutic agent for pain | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| EP-1908467-B1 | AGENT FOR TREATING HERPESVIRUS-DERIVED PAIN | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20090149532-A1 | HERPESVIRUS-DERIVED THERAPEUTIC AGENT FOR PAIN | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| CN-101198320-A | Herpesvirus-derived therapeutic agent for pain | JUNTENDO EDUCATIONAL FOUNDATIO (JP) | 2008-06-11 | — | — | CN | disclosed |
| EP-1908467-A1 | HERPESVIRUS-DERIVED THERAPEUTIC AGENT FOR PAIN | Juntendo Educational Foundation (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149532-A1 | HERPESVIRUS-DERIVED THERAPEUTIC AGENT FOR PAIN | RPL35, DDOST, HSPB1 | DUT 1015/4885SLC28A1 4650/4885SLC28A2 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.